1. Show article details.

    Decision on widespread Ebola vaccination in August at earliest - WHO

    Reuters – 5:42 AM ET 02/27/2015

    An independent advisory body will decide in August at the earliest on whether to recommend widespread introduction of Ebola vaccine, depending on results of clinical trials and the epidemic's course, the World Health Organization said on Friday.

  2. Show article details.

    6 reasons biotech stocks may soon tank

    MarketWatch – 11:08 AM ET 02/26/2015

    Risks are piling up as the sector has risen 60% in less than a year. The iShares Nasdaq Biotechnology ETF (IBB) has soared about 60% from lows during a bout of weakness last April, compared with an increase of 16% for the broader market. And this year has started off well, with a gain of 10%.

  3. Show article details.

    Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience

    PR Newswire – 8:00 AM ET 02/26/2015

    NEW BRUNSWICK, N.J., Feb. 26, 2015Johnson & Johnson (JNJ) today announced the formation of a new health and wellness platform that leverages the breadth of capabilities across its businesses.

  4. Show article details.

    FDA postpones key hearing on biosimilar copy of blockbuster drug

    Reuters – 7:30 AM ET 02/26/2015

    * Panel on Remsima had been scheduled for March 17. * FDA says new date will be announced in due course. * Remsima litmus test for acceptance of antibody biosimilars. By Ben Hirschler.

  5. Show article details.

    Bayer Reiterates Plans to Divest Plastics Business -- 2nd Update

    DJ Business News – 6:07 AM ET 02/26/2015

    LEVERKUSEN, Germany--German pharmaceutical group Bayer AG (BAYZF) reiterated on Thursday plans to divest itself of its high-tech plastics business, saying it would legally and economically separate the Material Science division by the end of August. "In the second half of this year, we intend to decide which of the possible variations to select for the stock market flotation--either an IPO or spin off" to shareholders, Chief Executive Marijn Dekkers said. He added that the company had...

  6. Show article details.

    South Carolina court orders J&J to pay $136 mln in Risperdal case

    Reuters – 5:07 AM ET 02/26/2015

    South Carolina's Supreme Court ordered Johnson & Johnson (JNJ) to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

  7. Show article details.

    Generic Copies of Remicade Go on Sale in Europe

    DJ Business News – 5:59 PM ET 02/25/2015

    Generic-drug makers have begun selling lower-priced copies of the blockbuster anti-inflammatory drug Remicade throughout Europe in recent days, a milestone in the emerging market for so-called "biosimilars," or generic versions of complex biotechnology drugs. An approaching wave of biosimilars in Europe and the U.S. could help contain drug spending, while eroding sales of expensive branded drugs such as Remicade, which is marketed by Merck& Co. and Johnson& Johnson.

  8. Show article details.

    Nodality Inc. Presents Data from Immuno-Oncology Program Applying Company’s Novel Single Cell Network Profiling (SCNP) Platform

    Business Wire – 8:00 AM ET 02/25/2015

    Nodality, Inc., which is focused on solving drug development challenges, today announced research results from its lead immuno-oncology efforts based on applications of the Company’s Single Cell Network Profiling technology.

  9. Show article details.

    Biosimilar copies of blockbuster drug launch in major EU markets

    Reuters – 3:31 AM ET 02/25/2015

    * New products are copies of J&J and Merck's Remicade. * Biosimilars expected to disrupt market for biotech medicines. By Ben Hirschler. Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars.

  10. Show article details.

    Impact of Global Economy on State GDP; Pension Metrics to Watch

    SourceMedia Bond Buyer – 7:04 PM ET 02/24/2015

    Discussion at a recent industry panel addressed possible impacts of the global economy on U.S. states and describe additional metrics to watch to monitor health of municipal pensions.

  11. Show article details.

    SolarCity, SunEdison shares fall after results

    MarketWatch – 6:37 PM ET 02/18/2015

    By Wallace Witkowski and Sue Chang, MarketWatch. EOG shares also fall on earnings miss, capex cut. SAN FRANCISCO-- Shares of alternative energy companies fell under pressure in the extended session Wednesday after SolarCity Corp. (SCTY) results and SunEdison Inc. (SUNE) sales fell short of Wall Street expectations.

  12. Show article details.

    S&P 500, Dow close lower after Fed minutes disappoint

    MarketWatch – 4:25 PM ET 02/18/2015

    By Anora Mahmudova and Sara Sjolin, MarketWatch. Fed likely to keep rates lower for longer than market expected. NEW YORK-- U.S. stocks ended marginally lower on Wednesday, as investors wrestled with interpreting minutes from the Federal Reserve's latest policy meeting.

  13. Show article details.

    MARKET SNAPSHOT: S&P 500, Dow Close Lower After Fed Minutes Disappoint

    DJ Business News – 4:25 PM ET 02/18/2015

    By Anora Mahmudova and Sara Sjolin, MarketWatch. Fed likely to keep rates lower for longer than market expected. NEW YORK-- U.S. stocks ended marginally lower on Wednesday, as investors wrestled with interpreting minutes from the Federal Reserve's latest policy meeting.

  14. Show article details.

    Time for Boston Scientific shares to break out?

    MarketWatch – 12:33 PM ET 02/18/2015

    J&J lawsuit was' major overhang' on stock, analysts say. For much of the past decade, Boston Scientific Corp. (BSX) has struggled to keep up with the valuations of its rivals in the medical device-making business, its stock languishing in the teens and even single digits at times while competitors' shares fly at much higher levels. On Tuesday Boston Scientific (BSX) removed what many stock analysts say was a "major overhang" on its stock by reaching a $600 million settlement in a $7 billion lawsuit,...

  15. Show article details.

    Boston Scientific to pay J&J $600 million to settle Guidant suit

    MarketWatch – 9:41 AM ET 02/18/2015

    Boston Scientific Corp. (BSX) agreed to pay Johnson& Johnson $600 million to settle a long-running lawsuit related to the 2006 acquisition of heart-device maker Guidant Corp. for $27 billion. J&J had sought more than $7 billion in damages after accusing Guidant of breaching their merger agreement by going with a higher offer from Boston Scientific (BSX). With the settlement announced Tuesday, J&J agreed to dismiss its lawsuit without any acknowledgment of liability by Guidant.

  16. Show article details.

    S&P 500 smashes targets, but that doesn't mean stocks have more steam

    MarketWatch – 8:02 AM ET 02/18/2015

    Critical information ahead of the U.S. market's open. Limping to the finish line, the S&P 500 closed above 2,100 for the first time ever on Tuesday, delivering year-end target goals to Goldman Sachs, Credit Suisse and Barclays nearly 11 months early. Deutsche Bank's 2,150 target is not far off, then we start digging into the 2,200 ballpark.

  17. Show article details.

    PRESS DIGEST-New York Times business news - Feb 18

    Reuters – 12:56 AM ET 02/18/2015

    The following are the top stories on the New York Times business pages. * A California nursing home fined by the state for substandard care and facing multiple lawsuits by patients and their families has taken the extreme measure of filing for bankruptcy protection in the face of millions of dollars in potential payouts.

  18. Show article details.

    Boston Scientific To Pay J&J $600 Million To Settle Guidant Suit -- Update

    DJ Business News – 5:44 PM ET 02/17/2015

    Boston Scientific Corp. (BSX) agreed to pay Johnson& Johnson $600 million to settle a long-running lawsuit related to the 2006 acquisition of heart-device maker Guidant Corp. for $27 billion. J&J had sought more than $7 billion in damages after accusing Guidant of breaching their merger agreement by going with the higher offer from Boston Scientific (BSX). As a result of the settlement announced Tuesday, J&J has agreed to dismiss its lawsuit without acknowledgment of liability by...

  19. Show article details.

    Fitch: Boston Scientific's Settlement Reduces Liability Risk but Also Liquidity

    Business Wire – 5:44 PM ET 02/17/2015

    Boston Scientific Corp.'s (BSX) ratings are unaffected by its recent settlement with Johnson & Johnson (JNJ) regarding litigation associated with BSX's acquisition of Guidant in 2006, according to Fitch Ratings. The settlement calls for BSX to pay $600 million to JNJ during 2015.

  20. Show article details.

    Fossil Group shares drop after earnings miss

    MarketWatch – 5:40 PM ET 02/17/2015

    By Wallace Witkowski and Victor Reklaitis, MarketWatch. Boston Scientific (BSX) shares rally on J&J settlement. SAN FRANCISCO-- Fossil Group Inc. (FOSL) shares dropped in the extended session Tuesday after the watch and accessories company's quarterly results fell short of Wall Street estimates.

Page:

Today's and Upcoming Events

  • Apr
    14

    JNJ to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Feb
    20

    JNJ ex-Dividend for $0.70 on 2/20/2015

    • Announce Date: 1/5/2015
    • Record Date: 2/24/2015
    • Pay Date: 3/10/2015
  • Jan
    20

    JNJ Earnings Conference Call at 8:30 AM Listen

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.